High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia

Leukemia Research

Volumn 38, Issue 6, 2014, Pages 691-693

  Van den Ancker, Willemijn ^a   Van Luijn, Marvin M ^a   Chamuleau, Martine E D ^a   Kelder, Angèle ^a   Feller, Nicole ^a   Terwijn, Monique ^a   Zevenbergen, Adri ^a   Schuurhuis, Gerrit Jan ^a   Ham, S Marieke van ^b   Westers, Theresia M ^a   Ossenkoppele, Gert J ^a   Van de Loosdrecht, Arjan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

HLA; Immune escape; Leukemia associated phenotype; Minimal residual disease

Indexed keywords

CLASS II ASSOCIATED INVARIANT CHAIN PEPTIDE; PEPTIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; FOLLOW UP; HUMAN; HUMAN CELL; LEUKEMIA ASSOCIATED PHENOTYPE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK;

CD4(+) T CELLS; HLA; IMMUNE ESCAPE; LEUKEMIA-ASSOCIATED PHENOTYPE; MINIMAL RESIDUAL DISEASE;

ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; RECURRENCE; RISK;

EID: 84900462604     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.03.014     Document Type: Article

References (11)

1. Feller N., Van Der Pol M.A., Van Stijn A., Weijers G.W.D., Westra A.H., Evertse B.W., et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004, 18:1380-1390.
2. Terwijn M., Van Putten W.L.J., Kelder A., Van der Velden V.H.J., Brooimans R.A., Pabst T., et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013, 31:3889-3897.
3. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-727.
4. Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest 2005, 23:413-419.
5. Kremer A.N., Van der Meijden E.D., Honders M.W., Goeman J.J., Wiertz E.J.H.J., Falkenburg J.H.F., et al. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO. Blood 2012, 120:3246-3255.
6. Nava-Parada P., Forni G., Knutson K.L., Pease L.R., Celis E. Peptide vaccine given with a toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 2007, 67:1326-1334.
7. Romagnoli P., Germain R.N., The C.L.I.P. region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med 1994, 180:1107-1113.
8. Chamuleau M.E.D., Souwer Y., Van Ham S.M., Zevenbergen A., Westers T.M., Berkhof J., et al. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 2004, 64:5546-5550.
9. Brouwer R.E., Zwinderman K.H., Kluin-Nelemans H.C., Van Luxemburg-Heijs S.A., Willemze R., Falkenburg J.H. Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: implications for adoptive immunotherapy. Exp Hematol 2000, 28:161-168.
10. Van Luijn M.M., Van den Ancker W., Chamuleau M.E.D., Zevenbergen A., Westers T.M., Ossenkoppele G.J., et al. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells. Cancer Res 2011, 71:2507-2517.
11. Van Luijn M.M., Chamuleau M.E.D., Thompson J.A., Ostrand-Rosenberg S., Westers T.M., et al. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica 2010, 95:485-493.